Application of isatin in preparation of medicine for treating polycystic ovarian syndrome
By using indigin solution to treat polycystic ovary syndrome, the problems of large and average side effects of existing treatment methods have been solved, and a significant improvement in polycystic ovary syndrome has been achieved, and the toxicity of indigin is low and the side effects are small.
Patent Information
- Application Number
- CN202510407716.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-04-02
- Publication Date
- 2025-06-13
AI Technical Summary
The current treatment options for polycystic ovary syndrome are limited, mainly focusing on the management of specific symptoms, and the commonly used hormone therapy in clinical practice has great side effects and average effects.
Inditin was used as the main ingredient, and the inditin solution was prepared by purification and ultrasonic mixing with sodium carboxymethylcellulose solution to treat polycystic ovary syndrome.
Inditin solution effectively improves the lesions of polycystic ovarian syndrome, manifested as concentration-dependent improvement of polycystic lesions in mice, and 100 mg/kg of inditin administration showed better efficacy than metformin, with low toxicity and fewer side effects.
Smart Images
Figure CN120131640A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedicine, and particularly relates to the application of isatin in the preparation of drugs for treating polycystic ovary syndrome. Background Art
[0002] Polycystic ovary syndrome (PCOS) is the most common reproductive endocrine disease among women of reproductive age, with a global prevalence of 10%-13%. It is characterized by hyperandrogenism, ovulatory dysfunction, irregular menstruation and polycystic ovarian morphology, and is often associated with metabolic disorders. The pathogenesis of polycystic ovary syndrome is usually related to factors such as obesity, insulin resistance, hyperandrogenism, chronic inflammation and oxidative stress. Polycystic ovary syndrome not only affects reproductive health, but also leads to metabolic-related health problems, such as obesity, insulin resistance, metabolic syndrome and type 2 diabetes. There is also evidence that patients with polycystic ovary syndrome have a higher risk of cardiovascular disease, atherosclerosis and hypertension. Hyperandrogenism is considered to be a key factor in the phenotypic manifestation of polycystic ovary syndrome and is thought to play a central role in its pathogenesis. Currently, the treatment options for polycystic ovary syndrome are limited and mainly focus on the management of specific symptoms. And most clinical treatments use hormone therapy, which has large side effects and general effects. Therefore, there is an urgent need to develop innovative treatment strategies.
[0003] Isatin was initially discovered in the marine animal lobster and later proved to be an active substance naturally present in mammalian body fluids and tissues. Isatin and its derivatives have a variety of proven pharmacological activities, including anti-apoptotic effects, anti-convulsant properties, antiviral activities, cytotoxicity, antibacterial effects, anti-glycation properties and potential anti-cancer activities. Isatin exists in multiple tissues of mammals, including the female ovary of the reproductive system. According to the principle of bioeconomic utilization, it is implied that isatin can be used for the treatment of diseases related to the female reproductive system. There is currently no report on the role of isatin in polycystic ovary syndrome. The inventors have long been concerned about the treatment of reproductive diseases and the development of related drugs. Through long-term research and experiments, it has been proved that isatin has a significant improvement effect on polycystic ovary syndrome, with low toxicity and small side effects, and has good application prospects. Isatin is a naturally occurring active substance with a variety of beneficial biological functions. Compared with the hormonal drugs for treating polycystic ovary clinically, the advantages of isatin are: better effect, lower toxicity and smaller side effects, and it has great value in developing new drugs. Summary of the Invention
[0004] The object of the present invention is to provide the application of isatin in the preparation of drugs for treating polycystic ovary syndrome, so as to provide reference value for the preparation of drugs with good effect, low toxicity and low side effects.
[0005] To solve the above technical problems, an embodiment of the present invention provides the application of isatin in the preparation of drugs for treating polycystic ovary syndrome.
[0006] The chemical formula of isatin is as follows:
[0007]
[0008] The present invention also provides a drug for treating polycystic ovary syndrome, which contains isatin or its derivatives.
[0009] The drug for treating polycystic ovary syndrome has the following dosage forms: oral preparations, injections, granules, pills, capsules, powders, sustained-release or controlled-release preparations, targeted preparations, and preparations for other administration routes.
[0010] The preparation method of the drug for treating polycystic ovary syndrome includes the following steps:
[0011] S1. Purification of isatin
[0012] S1.1. Add isatin to 50% ethanol, heat to 80°C, stir to dissolve, then slowly cool to precipitate red crystals, and filter to remove the supernatant.
[0013] S1.2. Repeat the operation steps of S1.1 for 2 - 3 times to obtain isatin crystals with a purity greater than 99%.
[0014] S2. Using 1% sodium carboxymethylcellulose solution as the solvent, add 100 mg of isatin to 10 ml of 1% sodium carboxymethylcellulose solution, and mix evenly by ultrasonic wave at 50°C to prepare a 10 mg / ml isatin solution, which is the drug for treating polycystic ovary syndrome.
[0015] Among them, in step S2, weigh 1 g of sodium carboxymethylcellulose, add it to 100 ml of distilled water, stir to dissolve, and prepare a 1% sodium carboxymethylcellulose solution.
[0016] The beneficial effects of the above technical solutions of the present invention are as follows:
[0017] The present invention provides an application of isatin in the preparation of a drug for treating polycystic ovary syndrome, effectively solving the solubility problem of isatin, uniformly and effectively dissolving isatin through simple operations, which is beneficial to efficient absorption in the body. Brief Description of the Drawings
[0018] Figure 1 It is a comparison diagram of ovarian tissues of each experimental group after the experiment in the present invention;
[0019] Figure 2 It is a comparison diagram of the ovarian appearance of each experimental group after the experiment in the present invention. Detailed Embodiments
[0020] To make the technical problems, technical solutions and advantages to be solved by the present invention clearer, the following will be described in detail with reference to the accompanying drawings and specific embodiments.
[0021] An embodiment of the present invention provides an application of isatin in the preparation of a drug for treating polycystic ovary syndrome.
[0022] The present invention also provides a drug for treating polycystic ovary syndrome, which contains isatin or its derivatives.
[0023] The drug for treating polycystic ovary syndrome has the following dosage forms: oral preparations, injections, granules, pills, capsules, powders, sustained-release or controlled-release preparations, targeted preparations and preparations for other administration routes.
[0024] The preparation method of the drug for treating polycystic ovary syndrome includes the following steps:
[0025] S1. Purification of isatin
[0026] S1.1. Add isatin to 50% ethanol, heat to 80 °C, stir to dissolve, and then slowly cool to precipitate red crystals. Filter to remove the supernatant.
[0027] S1.2. Repeat the operation steps of S1.1 for 2 - 3 times to obtain isatin crystals with a purity greater than 99%.
[0028] S2. Using a 1% sodium carboxymethylcellulose solution as a solvent, add 100 mg of isatin to 10 ml of a 1% sodium carboxymethylcellulose solution, and mix well by ultrasonic wave at 50 °C to prepare a 10 mg / ml isatin solution, which is the drug for treating polycystic ovary syndrome. In this step, weigh 1 g of sodium carboxymethylcellulose, add it to 100 ml of distilled water, stir to dissolve, and prepare a 1% sodium carboxymethylcellulose solution.
[0029] The following further elaborates the technical solution of the present invention with specific embodiments.
[0030] Sixty healthy female ICR mice, 3 weeks old, were purchased from the Experimental Animal Center of Nantong University. Five mice were housed in each standard polycarbonate cage with a corncob bedding and kept under standard environmental conditions (12:12 h light / dark cycle, temperature 22 - 25 °C, relative humidity 50 - 60%). Standard rodent feed and water were provided ad libitum. Before the experiment began, all mice were acclimated to the new animal facility for at least 1 week. Subsequently, the mice were randomly divided into 6 groups: a normal group, a polycystic ovary syndrome group, a metformin positive control group, and 3 indirubin treatment groups at different concentrations (25 mg / kg, 50 mg / kg, 100 mg / kg), with 10 mice in each group. Except for the normal group, the remaining groups were gavaged with 1 mg / kg b.w. of letrozole for modeling (letrozole solution was prepared with 1% sodium carboxymethylcellulose as the solvent). After 28 days, a letrozole-induced polycystic ovary syndrome model was successfully established. Subsequently, the normal group was gavaged with an equal volume of distilled water, while the treatment groups received indirubin at concentrations of 25, 50, and 100 mg / kg b.w. Treatment was administered by gavage for 28 consecutive days. The metformin group was given 150 mg / kg body weight. Metformin was gavaged for 28 consecutive days. After the experiment ended, the mice were anesthetized and sacrificed, and testicular sections were stained with hematoxylin-eosin to observe the drug effect.
[0031] The experimental results showed that Figure 1 in Figure 1 the middle Figure 1 the ovarian tissue of the model group ( Figure 1 upper middle) showed obvious polycystic-like characteristics compared with the normal group ( Figure 1 upper left), and the metformin positive control ( Figure 1 upper right) showed an obvious improvement effect. The indirubin administration groups (25 mg / kg ( Figure 1 lower left), 50 mg / kg ( Figure 2 lower middle), 100 mg / kg ( Figure 2 lower right)) showed a concentration-dependent improvement in the polycystic-like lesions of the mouse ovaries, and indirubin administration at 100 mg / kg showed a better drug effect than metformin at 150 mg / kg. Figure 2 in Figure 2 the left second Figure 2 visually, it could be seen that the ovaries of the model group (
[0032] The above is the preferred embodiment of the present invention. It should be noted that for those of ordinary skill in the art, without departing from the principle described in the present invention, several improvements and refinements can be made, and these improvements and refinements should also be regarded as the protection scope of the present invention.
Claims
1. Use of indigo carmine in the preparation of a drug for treating polycystic ovary syndrome.
2. A drug for treating polycystic ovary syndrome, characterized in that: Contains isatin or its derivatives.
3. The drug for treating polycystic ovary syndrome according to claim 2, characterized in that: The drug has the following preparation forms: oral preparations, injections, granules, pills, capsules, powders, sustained-release or controlled-release preparations, targeted preparations and preparations for other administration routes.
4. The drug for treating polycystic ovary syndrome according to claim 2, characterized in that: The preparation method thereof comprises the following steps: S1. Purification of isatin S1.
1. Add indigo carmine to 50% ethanol, heat to 80°C, stir to dissolve, then slowly cool to precipitate red crystals, and filter to remove the supernatant; S1.2, repeating step S1.1 2-3 times to obtain indigo carmine crystals with a purity greater than 99%; S2. Using 1% sodium carboxymethyl cellulose solution as solvent, 100 mg of indigo carmine is added to 10 ml of 1% sodium carboxymethyl cellulose solution, and ultrasonically mixed at 50°C to obtain a 10 mg / ml indigo carmine solution, which is a drug for treating polycystic ovary syndrome.
5. The drug for treating polycystic ovary syndrome according to claim 4, characterized in that: In step S2, 1 g of sodium carboxymethyl cellulose is weighed and added to 100 ml of distilled water, and stirred to dissolve to prepare a 1% sodium carboxymethyl cellulose solution.